Alnylam Pharmaceuticals, Inc.ALNYNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank21
Year-over-Year Change
Year-over-year free cash flow growth rate
Latest
-55.18%
↓ 1050% vs avg
Percentile
P21
Within normal range
Streak
2 qtr
Consecutive declineDecelerating
Average
5.81%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -55.18% |
| Q3 2025 | 124.45% |
| Q2 2025 | 209.55% |
| Q1 2025 | -22.68% |
| Q4 2024 | -362.57% |
| Q3 2024 | -65.98% |
| Q2 2024 | 222.92% |
| Q1 2024 | -109.49% |
| Q4 2023 | -113.18% |
| Q3 2023 | 557.01% |
| Q2 2023 | 58.47% |
| Q1 2023 | -17.42% |
| Q4 2022 | -16.56% |
| Q3 2022 | 5.10% |
| Q2 2022 | 26.54% |
| Q1 2022 | -9.90% |
| Q4 2021 | -7.45% |
| Q3 2021 | -20.28% |
| Q2 2021 | 47.36% |
| Q1 2021 | -74.60% |
| Q4 2020 | -17.98% |
| Q3 2020 | 19.24% |
| Q2 2020 | 42.81% |
| Q1 2020 | -13.20% |
| Q4 2019 | -7.36% |
| Q3 2019 | -181.77% |
| Q2 2019 | 215.00% |
| Q1 2019 | -23.72% |
| Q4 2018 | 5.65% |
| Q3 2018 | -58.87% |
| Q2 2018 | 29.12% |
| Q1 2018 | -42.94% |
| Q4 2017 | 0.22% |
| Q3 2017 | -20.78% |
| Q2 2017 | 24.75% |
| Q1 2017 | -38.96% |
| Q4 2016 | -2.49% |
| Q3 2016 | -15.78% |
| Q2 2016 | 13.28% |
| Q1 2016 | -69.93% |